FLUDARA

País: Israel

Idioma: inglés

Fuente: Ministry of Health

Ingredientes activos:

FLUDARABINE PHOSPHATE 50 MG/VIAL

Disponible desde:

SANOFI - AVENTIS ISRAEL LTD

Código ATC:

L01BB05

formulario farmacéutico:

POWDER FOR SOLUTION FOR INJ/INF

Vía de administración:

I.V

Fabricado por:

GENZYME EUROPE B.V., NETHERLANDS

Grupo terapéutico:

FLUDARABINE

indicaciones terapéuticas:

Palliative treatment of patients with CLL refractory to other therapy. Treatment of less malignant Non-Hodgkin lymphoma of stage 3 to 4 in patients who have not responded to standard therapy with at least one alkylating agent or in whom the disease progressed during or after standard therapy. Fludara is indicated for the initial treatment of patients with B- cell chronic lymphocytic leukaemia (CLL) or after first line therapy, in patients with sufficient bone marrow reserves.

Fecha de autorización:

2009-02-01